Accordingly, despite the significant clinical benefits of PARPi in patients with BRCA1-mutated breast and ovarian cancers, additional research is needed to identify predictive biomarkers that can help identify patients who are likely to benefit from PARPi therapy and to develop new strategies to overcome resistance to this therapy. This evidence concerns the gene BRCA1 and ovarian cancer.